Literature DB >> 8930005

Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine.

N Haddjeri1, P Blier, C de Montigny.   

Abstract

Mirtazapine (Org 3770, Remeron) is a new alpha2-adrenoceptor antagonist which is an effective antidepressant drug. An in vivo electrophysiological paradigm in the rat was used to assess the effects of acute and long-term treatment with mirtazapine on pre- and postsynaptic alpha2-adrenoceptors and to determine whether this drug can modulate serotonin (5-HT) neurotransmission. The acute administration of mirtazapine produced a rapid increase in both noradrenaline and 5-HT neurotransmission by blocking both alpha2-adrenergic auto- and heteroreceptors, resulting in an enhanced tonic activation of postsynaptic 5-HT receptors. Long-term administration showed that this tonic activation of postsynaptic 5-HT receptors was most likely enhanced after such a treatment, as a result of a sustained increase in 5-HT neuronal activity in the presence of and due to inactivated alpha2-adrenergic heteroreceptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8930005     DOI: 10.1097/00004850-199512004-00003

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  14 in total

1.  Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.

Authors:  Matthew A Seager; Vanessa N Barth; Lee A Phebus; Kurt Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

2.  Mutual independence of 5-HT(2) and α1 noradrenergic receptors in mediating deficits in sensorimotor gating.

Authors:  Sarah K Baisley; Katherine L Fallace; Abha K Rajbhandari; Vaishali P Bakshi
Journal:  Psychopharmacology (Berl)       Date:  2011-09-23       Impact factor: 4.530

3.  Depression treatment in patients with general medical conditions: results from the CO-MED trial.

Authors:  David W Morris; Nitin Budhwar; Mustafa Husain; Stephen R Wisniewski; Benji T Kurian; James F Luther; Kevin Kerber; A John Rush; Madhukar H Trivedi
Journal:  Ann Fam Med       Date:  2012 Jan-Feb       Impact factor: 5.166

Review 4.  A risk-benefit assessment of mirtazapine in the treatment of depression.

Authors:  S Kasper; N Praschak-Rieder; J Tauscher; R Wolf
Journal:  Drug Saf       Date:  1997-10       Impact factor: 5.606

Review 5.  Antidepressants and sleep: a qualitative review of the literature.

Authors:  Sue Wilson; Spilios Argyropoulos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats.

Authors:  Robin M Voigt; Amanda L Mickiewicz; T Celeste Napier
Journal:  Behav Brain Res       Date:  2011-07-12       Impact factor: 3.332

Review 7.  Psychopharmacological properties and therapeutic profile of the antidepressant venlafaxine.

Authors:  Claire Rampon; Bruno P Guiard; Basile Coutens; Antoine Yrondi
Journal:  Psychopharmacology (Berl)       Date:  2022-08-10       Impact factor: 4.415

8.  Context-dependent effects of a single administration of mirtazapine on the expression of methamphetamine-induced conditioned place preference.

Authors:  Robin M Voigt; T Celeste Napier
Journal:  Front Behav Neurosci       Date:  2012-01-13       Impact factor: 3.558

9.  Efficacy and safety of add on low-dose mirtazapine in depression.

Authors:  Prithpal S Matreja; Dinesh K Badyal; Randhir S Deswal; Arvind Sharma
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

10.  Treatment with selective serotonin reuptake inhibitors and mirtapazine results in differential brain activation by visual erotic stimuli in patients with major depressive disorder.

Authors:  Won Kim; Bo-Ra Jin; Wan-Seok Yang; Kyuong-Uk Lee; Ra-Hyung Juh; Kook-Jin Ahn; Yong-An Chung; Jeong-Ho Chae
Journal:  Psychiatry Investig       Date:  2009-06-30       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.